Stock views on Godawari Power & Ispat, Liberty Shoes, Torrent Pharma

Karvy Stock Broking on Godawari Power & Ispat - Target Rs 270

 

Karvy Stock Broking has recommended a buy rating on Godawari Power & Ispat, with price target of Rs 270, in its report

"Currently, Godawari Power & Ispat is trading at 1.2x its FY10 & 1x its FY11 BV. We retain our target price at Rs 270, based on 1.3x FY11 BV. The above mentioned steel price hikes possibility could the next trigger for the stock. We continue to be positive on the stock and upgrade our rating from Outperformer to BUY. Our price target of Rs 270/share would be 6x on FY11 EBITDA and 8x on FY11 EPS," says Karvy Stock Broking report.

Aditya Birla Money  on Liberty Shoes - Target Rs 125

Aditya Birla Money is bullish on Liberty Shoes and has recommended buy rating on the stock with a target of Rs 125, in its research report.

"At the CMP of Rs 107, the Liberty Shoes is trading at 19.58x of its trailing 12 monthearnings. The financials of Liberty shoes has shown consistent performance in thelast nine months. Historically the second half financials has been better than thefirst half financials. Considering the above factors, we are recommending a BUY on Liberty shoes for a 3 to 6 months target of RS 125," says Aditya Birla Money.

Firstcall Research  on Torrent Pharma - Target Rs 546

 

Firstcall Research has recommended buy rating on Torrent Pharmaceuticals with a target price of Rs 546 in its report.

Torrent Pharmaceuticals engages in the manufacture and sale of branded and unbranded generic pharmaceutical products in India and internationally. The company has posted a net profit of Rs 829.50 million for the quarter ended December 31, 2009 as compared to Rs 507 million for the quarter ended December 31, 2008. It has commissioned a new facility to manufacture human insulin at its Indrad manufacturing complex exclusively for supply to global healthcare major Novo Nordisk.

"At the current market price of Rs 475, the stock is trading at 16.71 x FY10E and 13.96 x FY11E respectively.  We expect that the company will keep its growth story in the coming quarters also. We recommend 'BUY' in this particular scrip with a target price of Rs 546 for Medium to Long term investment, "says Firstcall Research report.